Aminocoumarin: Difference between revisions

Jump to navigation Jump to search
m (Protected "Aminocoumarin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
 
Line 1: Line 1:
{{SI}}
{{SI}}
{{EH}}
 


[[Image:Novobiocin.png|thumb|left|[[Skeletal formula]] of [[novobiocin]]]]
[[Image:Novobiocin.png|thumb|left|[[Skeletal formula]] of [[novobiocin]]]]
Line 30: Line 30:
[[Category: Antibiotics]]
[[Category: Antibiotics]]


{{SIB}}
 


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WS}}
{{WS}}

Latest revision as of 22:04, 8 August 2012

WikiDoc Resources for Aminocoumarin

Articles

Most recent articles on Aminocoumarin

Most cited articles on Aminocoumarin

Review articles on Aminocoumarin

Articles on Aminocoumarin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Aminocoumarin

Images of Aminocoumarin

Photos of Aminocoumarin

Podcasts & MP3s on Aminocoumarin

Videos on Aminocoumarin

Evidence Based Medicine

Cochrane Collaboration on Aminocoumarin

Bandolier on Aminocoumarin

TRIP on Aminocoumarin

Clinical Trials

Ongoing Trials on Aminocoumarin at Clinical Trials.gov

Trial results on Aminocoumarin

Clinical Trials on Aminocoumarin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Aminocoumarin

NICE Guidance on Aminocoumarin

NHS PRODIGY Guidance

FDA on Aminocoumarin

CDC on Aminocoumarin

Books

Books on Aminocoumarin

News

Aminocoumarin in the news

Be alerted to news on Aminocoumarin

News trends on Aminocoumarin

Commentary

Blogs on Aminocoumarin

Definitions

Definitions of Aminocoumarin

Patient Resources / Community

Patient resources on Aminocoumarin

Discussion groups on Aminocoumarin

Patient Handouts on Aminocoumarin

Directions to Hospitals Treating Aminocoumarin

Risk calculators and risk factors for Aminocoumarin

Healthcare Provider Resources

Symptoms of Aminocoumarin

Causes & Risk Factors for Aminocoumarin

Diagnostic studies for Aminocoumarin

Treatment of Aminocoumarin

Continuing Medical Education (CME)

CME Programs on Aminocoumarin

International

Aminocoumarin en Espanol

Aminocoumarin en Francais

Business

Aminocoumarin in the Marketplace

Patents on Aminocoumarin

Experimental / Informatics

List of terms related to Aminocoumarin


Skeletal formula of novobiocin

Aminocoumarin is a class of antibiotics which act by an inhibition of the DNA Gyrase enzyme involved in the cell division in bacteria. They are derived from Streptomyces species, whose most well-known representative Streptomyces coelicolor was completely sequenced in 2002.[1] The Aminocoumarin antibiotics include

Mechanism of action

The Aminocoumarin antibiotics are known inhibitors of DNA gyrase. Antibiotics of the aminocoumarin family exert their therapeutic activity by binding tightly to the B subunit of bacterial DNA gyrase, thereby inhibiting this essential enzyme.[2] They compete with ATP for binding to the B subunit of this enzyme and inhibit the ATP-dependent DNA supercoiling catalysed by gyrase.[3] X-ray crystallography studies have confirmed binding at the ATP-binding site located on the gyrB subunit of DNA gyrase.[4]

Structure

The core of aminocoumarin antibiotics is made up of a 3-Amino-4,7-dihydroxycumarin ring, which is linked e.g. with a sugar in 7-Position and a benzoic acid derivative in 3-Position.

Clorobiocin is a natural antibiotic isolated from several Streptomyces strains and differs from novobiocin in that the methyl group at the 8 position in the coumarin ring of novobiocin is replaced by a chlorine atom, and the carbamoyl at the 3' position of the noviose sugar is substituted by a 5-methyl-2-pyrrolylcarbonyl group.[4]

Clinical use

The clinical use of these antibiotic class has been restricted due to their low water solubility, low activity against gram-negative bacteria[3] and toxiciy in vivo[5].


References

  1. Bentley SD, et al. Complete genome sequence of the model actinomycete "Streptomyces coelicolor" A3(2). Nature. 2002 (417)141–147 http://www.nature.com/nature/journal/v417/n6885/abs/417141a.html
  2. Galm, Ute, Heller, Stefanie, Shapiro, Stuart, Page, Malcolm, Li, Shu-Ming, Heide, Lutz Antimicrobial and DNA Gyrase-Inhibitory Activities of Novel Clorobiocin Derivatives Produced by Mutasynthesis Antimicrob. Agents Chemother. 2004 48: 1307-1312
  3. 3.0 3.1 Maxwell, A., and Lawson, D. M. (2003). The ATP-binding site of type II topoisomerases as a target for antibacterial drugs. Curr Top Med Chem, 3, 283-303.
  4. 4.0 4.1 F.T.F. Tsai, O.M. Singh, T.Skarzynski, A.J. Wonacott, S. Weston, A. Tucker, R.A. Pauptit, A.L. Breeze, J.P. Poyser, R. O'Brien et al., The high-resolution crystal structure of a 24-kDa gyrase B fragment from E. coli complexed with one of the most potent coumarin inhibitors, clorobiocin. Proteins 28 (1997), pp. 41–52
  5. A. Maxwell, The interaction between coumarin drugs and DNA gyrase. Mol. Microbiol. 9 (1993), pp. 681–686.



Template:WS